In turn, Fan et al. showed that RESV inhibited EGFR phosphorylation only in gefitinib-resistant lung cancer cells (NCI-H1975), but not in the cells with wild-type EGFR (A549, NCI-H358). This evidence concerns the gene EGFR and lung carcinoma.